Treatment decisions when prostate cancer is identified early
We use the term ‘low risk’ for a tumour in category cT1-2a, a Gleason score of 6 and a PSA level below 10 ng/ml.
When assessing a presumably localised tumour (i.e. a tumour confined to its place of origin), aggressiveness is just one factor we consider when deciding on a suitable treatment. Prostate cancer is usually slow-growing, so if a tumour is identified at a very early stage, the patient’s remaining life expectancy is also an important criterion.